论文部分内容阅读
用术中肝动脉栓塞化疗联合门静脉栓塞化疗治疗不能切除的原发性肝癌 32例 ,治疗后 AFP下降率为 78.3% ,肿瘤缩小率为 90 .6% ,半年、1年、2年生存率分别为 90 .6%、79.3%、52 .1% ;而同期行经皮股动脉插管肝动脉栓塞化疗治疗 30例 ,治疗后 AFP下降率为 57.1% ,肿瘤缩小率为 66.7% ,半年、1年、2年生存率分别为 70 .0 %、57.1% |16.7% ,两组 AFP下降率 ,肿瘤缩小率 ,半年、1年、2年生存率经统计学检验均有显著性差异 (P值均〈0 .0 5)。术中肝动脉栓塞化疗后 ,因肿瘤缩小而行二期切除的 3例 ,病理检查表现为肿瘤形成包膜 ,肿瘤组织坏死并纤维化 ,肿瘤周边组织未见癌细胞。提示此联合疗法疗效确切 ,操作简便 ,不需特殊器械 ,术中高选插管准确 ,异位栓塞等并发症少 ,能及时做病理检查 ,减少误诊误治 ,是治疗不能切除的原发性肝癌的好方法。
Intraoperative hepatic artery embolization chemotherapy combined with portal vein embolization chemotherapy was used to treat 32 cases of unresectable primary liver cancer. After treatment, the rate of decline of AFP was 78.3% and the tumor reduction rate was 90.6%. Six months, one year, and two years survival rates were respectively It was 90.6%, 79.3%, 52.1%. In the same period, 30 cases of transcatheter femoral artery catheterization and hepatic artery embolization chemotherapy were used. The rate of decline of AFP after treatment was 57.1%, and the tumor reduction rate was 66.7%. Six months and one year The two-year survival rates were 70.0 % and 57.1% | 16.7% respectively. There was a significant difference between the two groups in AFP decline rate, tumor shrinkage rate, and half-year, one-year, and two-year survival rates. <0. 0 5). After intraoperative hepatic artery embolization chemotherapy, two cases of secondary tumor resection were performed due to tumor shrinkage. The pathological examination showed that the tumor formed an envelope, necrosis and fibrosis of the tumor tissue, and no tumor cells were seen in the tumor surrounding tissue. It is indicated that this combination therapy is effective, easy to operate, requires no special equipment, is highly intubated, and has few complications such as ectopic embolism. It can promptly perform pathological examination and reduce misdiagnosis and mistreatment. It is a treatment for unresectable primary liver cancer. A good way.